AAAAAA

   
Results: 1-12 |
Results: 12
Farnesyl : protein transferase inhibitors as potential agents for the management of human prostate cancer
Authors: Sepp-Lorenzino, L Tjaden, G Moasser, MM Timaul, N Ma, Z Kohl, NE Gibbs, JB Oliff, A Rosen, N Scher, HI
Citation: L. Sepp-lorenzino et al., Farnesyl : protein transferase inhibitors as potential agents for the management of human prostate cancer, PROSTATE C, 4(1), 2001, pp. 33-43
Signaling pathways in apoptosis as potential targets-for cancer therapy
Authors: Huang, P Oliff, A
Citation: P. Huang et A. Oliff, Signaling pathways in apoptosis as potential targets-for cancer therapy, TR CELL BIO, 11(8), 2001, pp. 343
Drug-targeting strategies in cancer therapy
Authors: Huang, PS Oliff, A
Citation: Ps. Huang et A. Oliff, Drug-targeting strategies in cancer therapy, CUR OP GEN, 11(1), 2001, pp. 104-110
PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites
Authors: Wong, BK Defeo-Jones, D Jones, RE Garsky, VM Feng, DM Oliff, A Chiba, M Ellis, JD Lin, JH
Citation: Bk. Wong et al., PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites, DRUG META D, 29(3), 2001, pp. 313-318
The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy
Authors: Garsky, VM Lumma, PK Feng, DM Wai, J Ramjit, HG Sardana, MK Oliff, A Jones, RE DeFeo-Jones, D Freidinger, RM
Citation: Vm. Garsky et al., The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy, J MED CHEM, 44(24), 2001, pp. 4216-4224
Antitumor efficacy of a farnesyltransferase inhibitor in transgenic mice
Authors: Gibbs, JB Graham, SL Hartman, GD Koblan, KS Kohl, NE Omer, C Pellicier, A Windle, J Oliff, A
Citation: Jb. Gibbs et al., Antitumor efficacy of a farnesyltransferase inhibitor in transgenic mice, CANC DRUG, 8, 2001, pp. 65-70
A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo
Authors: DeFeo-Jones, D Garsky, VM Wong, BK Feng, DM Bolyar, T Haskell, K Kiefer, DM Leander, K McAvoy, E Lumma, P Wai, J Senderak, ET Motzel, SL Keenan, K Van Zwieten, M Lin, JH Freidinger, R Huff, J Oliff, A Jones, RE
Citation: D. Defeo-jones et al., A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo, NAT MED, 6(11), 2000, pp. 1248-1252
Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects
Authors: Prendergast, GC Oliff, A
Citation: Gc. Prendergast et A. Oliff, Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects, SEM CANC B, 10(6), 2000, pp. 443-452
Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS
Authors: Cohen-Jonathan, E Muschel, RJ McKenna, WG Evans, SM Cerniglia, G Mick, R Kusewitt, D Sebti, SM Hamilton, AD Oliff, A Kohl, N Gibbs, JB Bernhard, EJ
Citation: E. Cohen-jonathan et al., Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS, RADIAT RES, 154(2), 2000, pp. 125-132
Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl : protein transferase inhibitor
Authors: Omer, CA Chen, ZX Diehl, RE Conner, MW Chen, HY Trumbauer, ME Gopal-Truter, S Seeburger, G Bhimnathwala, H Abrams, MT Davide, JP Ellis, MS Gibbs, JB Greenberg, I Hamilton, K Koblan, KS Kral, AM Liu, DM Lobell, RB Miller, PJ Mosser, SD O'Neill, TJ Rands, E Schaber, MD Senderak, ET Oliff, A Kohl, NE
Citation: Ca. Omer et al., Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl : protein transferase inhibitor, CANCER RES, 60(10), 2000, pp. 2680-2688
Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis
Authors: Norgaard, P Law, B Joseph, H Page, DL Shyr, Y Mays, D Pietenpol, JA Kohl, NE Oliff, A Coffey, RJ Poulsen, HS Moses, HL
Citation: P. Norgaard et al., Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis, CLIN CANC R, 5(1), 1999, pp. 35-42
Famesyltransferase inhibitors: targeting the molecular basis of cancer
Authors: Oliff, A
Citation: A. Oliff, Famesyltransferase inhibitors: targeting the molecular basis of cancer, BBA-REV CAN, 1423(3), 1999, pp. C19-C30
Risultati: 1-12 |